MOLBIO DIAGNOSTICS Q2 FY27 CONCALL: REAFFIRMS 25% FY27 REVENUE GROWTH & 24–25% EBITDA MARGIN GUIDANCE; EXPECTS STRONG H2 RECOVERY FROM ₹100 CR DELAYED GOVERNMENT BILLING, HEPATITIS B & C ORDERS; TARGETS NEW DIAGNOSTIC PLATFORM APPROVALS WITHIN 4–5 MONTHS & OPTRASCAN COMMERCIAL RAMP-UP IN FY28